{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Regadenoson+infusion",
    "query": {
      "intervention": "Regadenoson infusion"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 25,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Regadenoson+infusion&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-11T05:51:33.367Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00208299",
      "title": "ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Regadenoson",
          "type": "DRUG"
        },
        {
          "name": "Adenosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1231,
      "start_date": "2003-10",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2009-11-26",
      "last_synced_at": "2026-09-11T05:51:33.367Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00208299"
    },
    {
      "nct_id": "NCT01161121",
      "title": "Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "adenosine",
          "type": "DRUG"
        },
        {
          "name": "regadenoson",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Louis University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2010-07",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2017-06-23",
      "last_synced_at": "2026-09-11T05:51:33.367Z",
      "location_count": 2,
      "location_summary": "Jacksonville, Florida • St Louis, Missouri",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01161121"
    },
    {
      "nct_id": "NCT01482169",
      "title": "Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "FFR Measurement with IV Adenoscan® then with Regadenoson",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ochsner Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2012-03",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2018-05-11",
      "last_synced_at": "2026-09-11T05:51:33.367Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01482169"
    },
    {
      "nct_id": "NCT01021618",
      "title": "Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Myocardial Ischemia"
      ],
      "interventions": [
        {
          "name": "Regadenoson",
          "type": "DRUG"
        },
        {
          "name": "Symptom-limited exercise",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hartford Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2010-01",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2013-03-21",
      "last_synced_at": "2026-09-11T05:51:33.367Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01021618"
    },
    {
      "nct_id": "NCT01489176",
      "title": "Regadenoson Real Time Perfusion Imaging Trial-Optison",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Myocardial Perfusion Abnormalities"
      ],
      "interventions": [
        {
          "name": "Regadenoson; Optison",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2012-07-31",
      "completion_date": "2014-12-01",
      "has_results": true,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-09-11T05:51:33.367Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • Omaha, Nebraska",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01489176"
    },
    {
      "nct_id": "NCT01021865",
      "title": "Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coronary Artery Disease",
        "Diabetes Mellitus Type 2"
      ],
      "interventions": [
        {
          "name": "Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "40 Years to 60 Years"
      },
      "enrollment_count": 33,
      "start_date": "2010-02",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2015-07-07",
      "last_synced_at": "2026-09-11T05:51:33.367Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01021865"
    },
    {
      "nct_id": "NCT01026012",
      "title": "Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiac Function"
      ],
      "interventions": [
        {
          "name": "regadenoson",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 40,
      "start_date": "2009-12",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2022-08-02",
      "last_synced_at": "2026-09-11T05:51:33.367Z",
      "location_count": 1,
      "location_summary": "Westminster, Maryland",
      "locations": [
        {
          "city": "Westminster",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01026012"
    },
    {
      "nct_id": "NCT01370265",
      "title": "Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Regadenoson",
          "type": "DRUG"
        },
        {
          "name": "Adenosine",
          "type": "DRUG"
        },
        {
          "name": "N-13 ammonia",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2011-02",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2013-09-05",
      "last_synced_at": "2026-09-11T05:51:33.367Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01370265"
    },
    {
      "nct_id": "NCT01566890",
      "title": "Microvascular Blood Flow in Sickle Cell Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Sickle Cell Anemia"
      ],
      "interventions": [
        {
          "name": "regadenoson infusion with contrast-enhanced ultrasound",
          "type": "DRUG"
        },
        {
          "name": "contrast-enhanced ultrasound",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Versiti Blood Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 91,
      "start_date": "2012-07",
      "completion_date": "2020-11-16",
      "has_results": true,
      "last_update_posted_date": "2024-06-26",
      "last_synced_at": "2026-09-11T05:51:33.367Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01566890"
    },
    {
      "nct_id": "NCT00763035",
      "title": "Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Asthma",
        "Chronic Obstructive Pulmonary Disease (COPD)",
        "Angina"
      ],
      "interventions": [
        {
          "name": "Regadenoson",
          "type": "DRUG"
        },
        {
          "name": "Dobutamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 14,
      "start_date": "2009-01",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2018-09-26",
      "last_synced_at": "2026-09-11T05:51:33.367Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00763035"
    }
  ]
}